Elixir Medical has introduced the DynamX® Sirolimus-Eluting Coronary Bioadaptor System, which has received Breakthrough Device Designation from the FDA.

This designation aims to enhance coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease from discrete de novo native coronary artery lesions.

The DynamX bioadaptor works in three phases to return the diseased vessel to a more normal condition. Initially, it establishes maximum blood flow post-implantation to alleviate coronary artery disease symptoms.

As the bioadaptor becomes encapsulated and its absorbable polymer coating is resorbed, its helical strands unlock and separate.

This promotes vessel growth and adaptation to maintain optimal blood flow. In its final phase, the bioadaptor provides dynamic support to the vessel through its separated helical strands, restoring vessel viability, hemodynamic modulation, and promoting plaque stabilization and regression.

The FDA's Breakthrough Device Designation expedites the review process for innovative technologies aimed at improving treatment or diagnosis of life-threatening or severely debilitating conditions like coronary artery disease, affecting a significant portion of the U.S. population.

The importance of innovative approaches beyond traditional stent technologies to improve patient outcomes. He expressed appreciation for the FDA's recognition of the bioadaptor technology's potential and looks forward to collaborating with regulatory bodies and medical societies to bring this advancement to U.S. patients expeditiously.

Recent clinical data presented at EuroPCR 2024 highlighted the DynamX bioadaptor's superiority over standard drug-eluting stents in reducing adverse events, particularly in critical artery locations such as the left anterior descending (LAD) artery.

These findings underscore the bioadaptor's ability to enhance vessel health and performance by restoring pulsatility, compliance, and adaptive blood flow.

While the DynamX Coronary Bioadaptor System is currently CE-marked, it is not yet available for sale in the U.S., pending further regulatory processes.

 

 

 

 

Source: businesswire.com

Report Abuse